TOPLINE: Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4) inhibitors in patients with type 2 diabetes, but the drug did reduce the risk for its progression by 22% in patients with existing retinopathy…
